<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00491582</url>
  </required_header>
  <id_info>
    <org_study_id>320000-109522/1</org_study_id>
    <nct_id>NCT00491582</nct_id>
  </id_info>
  <brief_title>The Effects of Growth Hormone (GH) on Lipid Depots</brief_title>
  <official_title>The Effect of Growth Hormone (GH) on Intramyocellular Lipids (IMCL), Intrahepatocellular Lipids (IHCL) and Visceral Fat Mass in Relation to Insulin Resistance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Inselspital, Berne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Swiss National Science Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Inselspital, Berne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims at investigating the effect of growth hormone on lipid-content of muscle and&#xD;
      liver as well as visceral fat mass in relation to insulin sensitivity.&#xD;
&#xD;
      In addition, hormonal regulation and free fatty availability is assessed during a physical&#xD;
      exercise at 50-60% VO2max.&#xD;
&#xD;
      Finally, the value of physical exercise in diagnosing growth hormone deficiency is&#xD;
      investigated.&#xD;
&#xD;
      Hypothesis: 1) Lipid content of muscle and liver change with physical exercise and exercise&#xD;
      capacity and free fatty availability will influence these changes. 2)Growth hormone&#xD;
      replacement therapy will predominantly reduce visceral fat mass and increase free fatty&#xD;
      availability.&#xD;
&#xD;
      3)Free fatty availability during exercise will be reduced in growth hormone deficient&#xD;
      patients 4)Physical exercise may be an alternative way to diagnose growth hormone deficiency&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Using the two-step hyperinsulinaemic-euglycaemic clamp technique hepatic and peripheral&#xD;
      insulin sensitivity is assessed.&#xD;
&#xD;
      Lipid depots (skeletal muscle and liver) are measured by MR-spectroscopy, visceral fat mass&#xD;
      by MR-imaging.&#xD;
&#xD;
      Exercise capacity ist measured on a treadmill. Counterregulatory hormones, glucose and free&#xD;
      fatty acids are measured during a 2h physical exercise at 50-60 VO2max Identical&#xD;
      investigations are performed in adult growth hormone (GH) deficient patients before and after&#xD;
      six months GH replacement therapy, in sedentary matched control subjects and in endurance&#xD;
      trained athletes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determination of visceral fat mass by MRI,Determination of IMCL and IHCL by MR Spectroscopy, Determination of peripheral and hepatic insulin sensitivity by two step hyperinsulinemic euglycemic clamp</measure>
    <time_frame>2008 - 2009</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>maximal exercise capacity</measure>
    <time_frame>2008 - 2009</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of serum alphaKlothe by an ELISA</measure>
    <time_frame>2008 - 2013</time_frame>
    <description>Measured in pg/mL</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Growth Hormone Deficiency</condition>
  <arm_group>
    <arm_group_label>Athletes, controls, patients</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Sedentary controls: age, BMI, Gender and waist matched (to the growth hormone deficient patients) healthy control subjects Endurance trained athletes: minimal &gt;50 mlO2/KG body weight</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Growth hormone replacement therapy in growth hormone deficient patients only.</intervention_name>
    <description>Genotropin once/daily sc., titration scheme according to the consensus guidelines of the GH and IGF-research society Duration: 6 months</description>
    <arm_group_label>Athletes, controls, patients</arm_group_label>
    <other_name>Genotropin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female patients with proven GH-deficiency defined as a peak GH of less than&#xD;
             3mU/l during an insulin provocation test with nadir plasma glucose less than 2.2&#xD;
             mmol/l and additionally, stable conventional replacement therapy including corticoids,&#xD;
             thyroxin and gonadal hormones as needed.&#xD;
&#xD;
          -  Ability to perform an exercise test on a treadmill or a walking band.&#xD;
&#xD;
          -  Willingness to participate in the study and to give written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Active neoplasia&#xD;
&#xD;
          -  Severe cardiovascular disease (unstable coronary heart disease, heart failure NYHA&#xD;
             III-IV)&#xD;
&#xD;
          -  Type 2 Diabetes mellitus&#xD;
&#xD;
          -  Haemophilia or other coagulation disorder&#xD;
&#xD;
          -  Inability to exercise&#xD;
&#xD;
          -  Contraindications to exposure to a 3-T magnetic field (Pace-Makers, osteosynthetic&#xD;
             material)&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  Women in childbearing age unless on a continuous contraceptive therapy or surgically&#xD;
             sterilised.&#xD;
&#xD;
          -  Abnormal liver or renal function (Creatinine &gt;130mmol/L, normal reference 45-93mmol/L;&#xD;
             ASAT and ALAT &gt; 3 times the upper reference limit).&#xD;
&#xD;
          -  Major depression, psychosis and other severe personality disorders&#xD;
&#xD;
          -  Excessive alcohol consumption (&gt;60g/d) or drug-abuse&#xD;
&#xD;
          -  Refusal to give written consent&#xD;
&#xD;
          -  Patients, who are not suitable for the study according to the study physician&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emanuel R Christ, Prof,MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Abt. f체r Endokrinologie, Diabetologie und Klin. Ern채hrung, Inselspital, Berne</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Abt. f체r Endokrinologie, Diabetologie und Klin. Ern채hrung, Inselspital</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <study_first_submitted>June 25, 2007</study_first_submitted>
  <study_first_submitted_qc>June 25, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2007</study_first_posted>
  <last_update_submitted>August 12, 2013</last_update_submitted>
  <last_update_submitted_qc>August 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 13, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Inselspital, Berne</investigator_affiliation>
    <investigator_full_name>Emanuel Christ</investigator_full_name>
    <investigator_title>Prof. Emanuel Christ, MD, PhD</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

